V43Kan u de vragen beantwoorden voor het volgende «coronadebat»? X Noot 1 Brief van de Minister van Volksgezondheid, Welzijn en Sport, 6 maart 2023, «Reactie op verzoek commissie over de veiligheid van mRNA-vaccins en de bevoegdheden van de Wereldgezondheidsorganisatie (WHO)». X Noot 2 Journal of Hepatology, (Nyein et al.), 27 augustus 2022, «Severe de novo liver injury after Moderna vaccination – not always autoimmune hepatitis». X Noot 3 MDPI, (Mörz), 1 oktober 2022, «A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19». X Noot 4 International Journal of Dermatology, (Metin, Celepli), 24 januari 2022, «A case of morphea following the COVID-19 mRNA vaccine: on the basis of viral spike proteins». X Noot 5 Journal of Cutaneous Immunology and Allergy, (Yamamoto et al.), 8 juni 2022, «Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion». X Noot 6 Cell, (Röltgen et al.), 17 maart 2022, «Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination». X Noot 7 Biomedicines, (Fertig et al.), 28 juni 2022, «Vaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination». X Noot 8 European Medicines Agency, 2020, Comirnaty (COVID-19 mRNA vaccine nucleoside modified). X Noot 9 Committee for Medicinal Products for Human Use, 2012, Assessment report EMA. CHMP/709596/2012. European Medicines Agency. X Noot 10 Vaccines, (Magen et al.), 16 juli 2022, «Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis». X Noot 11 ACS Publications (Nance, Meier), 6 april 2021, «Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines». X Noot 12 Journal of Immunology, (Bansal et al.), 15 november 2021, «Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines». X Noot 13 Blood Advances, (Appelbaum et al.), 12 april 2022, «SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia». X Noot 14 Circulation, (Yonker et al.), 4 januari 2023, «Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis». X Noot 15 Frontiers in Immunology, (Buhre et al.), 12 januari 2023, «mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine». X Noot 16 Science Immunology, (Irrgang et al.), 27 januari 2023, «Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination». X Noot 17 International Journal of Molecular Sciences, (Cosentino, Marino), 17 september 2022, «Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?». X Noot 18 International Journal of Molecular Sciences, (Baumeier et al.), 22 juni 2022, «Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series». X Noot 19 Jama Pediatrics, (Hanna et al.), 26 september 2022, «Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk» X Noot 20 Clinical Pharmacokinetics, (Naasani), 12 juli 2022, «Establishing the Pharmacokinetics of Genetic Vaccines is Essential for Maximising their Safety and Efficacy». X Noot 21 ICH Harmonised Tripartite Guideline. 11 juni 2019, «Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. M 3 (R2) Current Step 4 Version». X Noot 22 Viruses, (Focosi et al.), 19 januari 2022, «Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence». X Noot 23 Frontiers in Immunology, (Russell et al.), 30 november 2020, «Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection». X Noot 24 The Lancet, (Stein et al.), 16 februari 2023, «Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis». X Noot 25 Journal of Autoimmunity, (Vatti et al.), september 2017, «Original antigenic sin: A comprehensive review». X Noot 26 The Journal of Clinical investigation, (Aguilar-Bretones et al.), 3 januari 2023, «Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity». X Noot 27 MedRxiv, (Tamandjou et al.), 12 januari 2023, «Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France». X Noot 28 MedRxiv, 1 november 2022 «COVID-19 primary series and booster vaccination and immune imprinting». X Noot 29 The New England Journal of Medicine (Offit), 9 februari 2023, «Bivalent Covid-19 Vaccines – A Cautionary Tale». X Noot 30 NOS, 22 januari 2022, «Zorgen over nieuwe coronavarianten; wat betekent dit voor werking van vaccins». X Noot 31 RIVM, 13 maart 2023, «Prik tegen corona (coronaprik) – «Wat betekent het dat de vaccins vernieuwd zijn?»» ( https://www.rivm.nl/covid-19-vaccinatie/vragen-achtergronden/herhaalprik-tegen-corona ). X Noot 32 Kamerstuk 25 295, nr. 1332 .